Revolution Medicines, Inc. (BIT:1RVMD)
Italy · Delayed Price · Currency is EUR | Market Cap | 38.14B +296.5% |
| Revenue (ttm) | 173.97M |
| Net Income | -1.65B |
| EPS | -8.15 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 44 |
| Open | 184.25 |
| Previous Close | 185.95 |
| Day's Range | 184.25 - 185.00 |
| 52-Week Range | 39.40 - 193.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)... [Read more]
News
Revolution Medicines price target raised to $350 from $280 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Revolution Medicines (RVMD) to $350 from $280 and keeps a Buy rating on the shares. The firm says Rasonque…
Revolution Medicines price target raised to $272 from $255 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Revolution Medicines (RVMD) to $272 from $255 and keeps an Overweight rating on the shares. Rasonque’s first commercial quarter came in well…
This pancreatic cancer treatment is on track for ‘one of the best drug launches of all time'
Revolution Medicines' brand-new treatment brought in far higher sales than expected in its first few weeks on the market.
Revolution Medicines price target raised to $321 from $260 at RBC Capital
RBC Capital raised the firm’s price target on Revolution Medicines (RVMD) to $321 from $260 and keeps an Outperform rating on the shares. The Rasonque launch far exceeded RBC’s expectations,…
Revolution Medicines price target raised to $270 from $250 at TD Cowen
TD Cowen raised the firm’s price target on Revolution Medicines (RVMD) to $270 from $250 and keeps a Buy rating on the shares. Rasonque’s $198MM sales from 5 weeks in…
Revolution Medicines price target raised to $298 from $275 at Guggenheim
Guggenheim raised the firm’s price target on Revolution Medicines (RVMD) to $298 from $275 and keeps a Buy rating on the shares.
Revolution Medicines price target raised to $340 from $320 at Evercore ISI
Evercore ISI analyst Cory Kasimov raised the firm’s price target on Revolution Medicines (RVMD) to $340 from $320 and keeps an Outperform rating on the shares.
Revolution Medicines price target raised to $274 from $264 at BofA
BofA raised the firm’s price target on Revolution Medicines (RVMD) to $274 from $264 and keeps a Buy rating on the shares.
Revolution Medicines price target raised to $222 from $210 at Piper Sandler
Piper Sandler raised the firm’s price target on Revolution Medicines (RVMD) to $222 from $210 and keeps an Overweight rating on the shares. The firm notes the company reported Q3…
Revolution Medicines Earnings Call Transcript: Q3 2026
RASONQUE launched after FDA approval, generating $197.6M in net product revenue in about five weeks, though early demand includes finite transition and backlog cohorts. Cash and securities totaled $3.7B, while broad clinical development and international launch preparations continue.
Revolution Medicines Earnings release: Q3 2026
Revolution Medicines released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Revolution Medicines Quarterly report: Q3 2026
Revolution Medicines has published its Q3 2026 quarterly earnings report on November 4, 2026.
Revolution Medicines reports Q3 EPS ($1.90), consensus ($2.38)
Reports Q3 revenue $197.56M, may not compare to consensus $27.35M. Cash, cash equivalents and marketable securities were $3.7B as of September 30. “The U.S. approval and launch of RASONQUE marked…
Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
Received U.S. FDA approval and launched RASONQUE® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or who are not candidates fo...
Revolution Medicines to Participate in November 2026 Investor Conferences
REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innov...
Revolution Medicines presents subgroup analyses from RASolute 302 trial
Revolution Medicines (RVMD) announced that exploratory subgroup analyses from the Phase 3 RASolute 302 trial were presented as a late-breaking abstract at the European Society for Medical Oncology, or...
Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026
REDWOOD CITY, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innov...
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innov...
Revolution Medicines begins treating patients in RASolve 308 trial
Revolution Medicines (RVMD) announced that it has begun treating patients in RASolve 308, a global Phase 3 clinical trial evaluating zoldonrasib, an investigational, RAS G12D-selective inhibitor, in c...
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer
REDWOOD CITY, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innov...
Revolution Medicines price target raised to $241 from $240 at Truist
Truist raised the firm’s price target on Revolution Medicines (RVMD) to $241 from $240 and keeps a Buy rating on the shares ahead of its Q3 results. Investor feedback keeps…
Revolution Medicines initiated with an Outperform at William Blair
William Blair initiated coverage of Revolution Medicines (RVMD) with an Outperform rating. The firm believes the company will maintain its dominant position and move into earlier lines of therapy like...
Revolution Medicines receives positive CHMP opinion for RASONQUE
Revolution Medicines (RVMD) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion of RASONQUE once-daily oral tablets as a monoth...
EMA recommends approval of Revolution's pancreatic cancer drug
A European Medicines Agency committee on Thursday recommended approval of Revolution Medicines' Rasonque in the EU for adults with pancreatic cancer that has spread and worsened after at least on...
Revolution Medicines' RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
Recommendation based on results from Phase 3 RASolute 302 trial, which demonstrated a 60% reduction in risk of death compared with chemotherapy in the overall study population with statistically signi...